“…However, many other signaling mechanisms could affect the efficacy of vascular-targeted therapies, like the competition between pro- and anti-angiogenic VEGF-A isoforms, cross-family PDGF-VEGFR2 signaling, and paracrine signaling between the endothelium and adipocytes/macrophages, as we detailed earlier. To more accurately predict how obese adipose tissue responds to vascular-targeted therapies, future models should integrate the ODEs that have been developed to model: the impact of VEGFR heterogeneity on anti-VEGF efficacy ( Weddell and Imoukhuede, 2014 ) the differential VEGF signal transduction by VEGFR homo- and hetero-dimers ( Mac Gabhann and Popel, 2007 ; Mamer et al, 2019b ), the significance of VEGF-A 165b in ischemic conditions ( Chu et al, 2016 ; Clegg et al, 2017 ), the effect of cross-family PDGF-VEGFR binding on VEGFR occupancy ( Mamer et al, 2017 ), the VEGFR mechanisms inducing macrophage migration ( Weddell et al, 2018 ), the recruitment of macrophages to the lymphatic endothelium ( Bianchi et al, 2015 ), and the pro- and anti-inflammatory signaling of adipose tissue macrophages ( Díaz et al, 2009 ). Modeling these molecules, interactions, and cell responses would allow us to determine which mechanisms in adipose tissue could be targeted to normalize VEGF:VEGFR signaling in obesity.…”